China NMPA granted Priority Review for Zai lab’s Repotrectinib for the treatment of ROS1-positive NSCLC

Elevar Therapeutics filed the NDA for Rivoceranib and Camrelizumab combination in 1L HCC

AstraZeneca’s TAGRISSO + Chemo combo demonstrated encouraging PFS data in EGFR-mutated Lung Cancer

FDA granted FTD for ImmPACT Bio’s CAR-T therapy for R/R Aggressive B Cell Lymphoma

Merck and Hummingbird Bioscience join hands to develop anti-HER3 mAb in SqNSCLC

China NMPA granted Breakthrough Designation for Innovent’s KRASG12Ci for previously treated CRC